Mitchell H. Finer, Ph.D.
About Mitchell H. Finer, Ph.D.
Mitchell H. Finer, Ph.D. - Title and Role
Mitchell H. Finer, Ph.D., is the President of Research and Development. He oversees the strategic planning and execution of research initiatives within the company. His role involves steering the development of cutting-edge therapies and ensuring alignment with the overarching vision of the company.
Education and Academic Background of Mitchell H. Finer, Ph.D.
Mitchell H. Finer, Ph.D., earned his Bachelor of Science degree with honors and his Ph.D. degree from the University of Leeds in England. His academic background laid the foundation for his extensive career in immunology, regenerative medicine, and biotechnology.
Experience and Expertise in Cell and Gene Therapy
Mitchell H. Finer, Ph.D., has over 30 years of experience in biotech and academic immunology. He has a deep expertise in cell and gene therapy, having led early development and application of chimeric antigen receptor (CAR) technology to T-cells and stem cells. His work has significantly advanced the field, particularly in the development of novel CAR- and TCR-based T cell therapies for solid tumors.
Leadership at Life Edit Therapeutics and Role in R&D
Dr. Mitchell H. Finer served as the Chief Executive Officer at Life Edit Therapeutics, where he played a crucial role in leading the organization’s efforts in research and development. His leadership was pivotal in advancing the company's therapeutic programs and driving innovation in the field.
Recognitions, Publications, and Patents
Mitchell H. Finer, Ph.D., has been recognized as a top R&D leader by Endpoints News. He is the author of more than thirty scientific publications and is the inventor on thirteen issued U.S. patents and three published U.S. patent applications. These achievements underscore his contributions to the field of biotechnology and his role as a thought leader in scientific research.